PitchSend

argenx SE Investor Day Presentation Deck

Significant Market Opportunity Across Myositis Subsets REACHING PATIENTS + 33K Estimated eligible myositis patients in U.S. argenx DEFINING NEW BIOLOGY Building a Basket Trial Concept 1 IMNM: 4K pts U.S. Role of autoantibody is best-characterized in IMNM IMNM anchors market opportunity 2 ASYS: 8K pts U.S. Basket trial approach to include ASYS and DM as well Reaching more patients with high unmet need 3 DM: 21K pts U.S. Efgartigimod may allow us to redefine all three myositis subsets as being truly IgG- mediated 35

View entire presentation